Get your free personalized podcast brief
We scan new podcasts and send you the top 5 insights daily.
The LIDERA trial's early, robust success with the oral SERD giredestrant in adjuvant therapy is surprising. In the metastatic setting, these drugs primarily benefit tumors with ESR1 mutations, which are acquired after therapy and rare at diagnosis. This paradoxical result suggests a different mechanism of action in early-stage disease and necessitates longer follow-up to confirm the finding.
Related Insights
The ELEGANT trial enrolls all high-risk ER-positive patients, not just those with ESR1 mutations. The rationale is that unlike in metastatic disease, early breast cancer is fundamentally ER-driven. Elicestrin targets both wild-type and mutant ER, making the mutation status less critical for efficacy in this earlier setting.
The Lidara study showed SERD benefit in patients without pre-existing ESR1 mutations. Success is likely multifactorial: SERDs are more effective and better tolerated than AIs. Critically, they also prevent the most common resistance mechanism—the acquisition of ESR1 mutations—from developing in the first place, altering the disease's future trajectory.
The SERENA-6 strategy of switching to an oral SERD upon detecting an ESR1 mutation in ctDNA—before clinical progression—is a novel concept. It forces oncologists to grapple with the idea of 'molecular progression' and whether this biomarker-led switch truly alters the disease's natural history.
Ladera showed a significant benefit for geridesterant over standard endocrine therapy in early breast cancer with an efficacy signal similar to initial readouts for CDK4/6 inhibitors. Since CDK4/6 inhibitors were excluded, this creates a clinical debate: are these treatments interchangeable, sequential, or for different populations?
Experts found the early and significant separation of survival curves in the adjuvant Ladera trial for giredestrant "stunning." This rapid divergence suggests a powerful biological effect, drawing parallels to the historically impactful introduction of aromatase inhibitors over tamoxifen.
An ESR1 mutation locks the estrogen receptor in a permanently "on" state, independent of estrogen. This renders aromatase inhibitors (AIs) ineffective but means therapies that degrade the receptor itself, like SERDs, can still be effective treatment options.
While the Lidera trial showed a benefit for the oral SERD giredestrant in the adjuvant setting, experts advise caution before changing practice. The trial's control arm (standard endocrine therapy) does not reflect the current standard of care for high-risk patients, which now includes CDK4/6 inhibitors, making a direct comparison difficult.
In the EMBER-3 trial, the combination of the oral SERD imlunestrant and the CDK4/6 inhibitor abemaciclib showed a 41% reduction in progression risk versus the SERD alone. Critically, this benefit was observed regardless of the patient's ESR1 mutation status, indicating a broader mechanism of action.
The Avera trial's strong results for jiridestrant were overwhelmingly driven by patients with ESR1 mutations. Analysis revealed minimal benefit for patients without the mutation (wild-type), suggesting the mutation is a key predictive biomarker and the drug may not be for "all comers."
While the LADERA study showed a benefit for oral SERD gerodestrant over standard endocrine therapy, its applicability is questionable. In the metastatic setting, adding an oral SERD to a CDK inhibitor did not show a statistically significant benefit over an AI plus CDK, raising doubts about its added value in the adjuvant CDK era.
